Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders - Rubin, D. T.; Dubinsky, M. C.; Danese, S.; Saad-Hossne, R. [UNESP]; Ponce de Leon, D.; Maller, E.; Lawendy, N.; Kwok, K.; Su, C. (Oxford Univ Press, 2020)